CD86 and neoplasm: Consequently, our study seeks to evaluate the impact of anti-CTLA4/NKG2A aptamers on immune checkpoint interactions, specifically examining CTLA4-CD80/CD86 and NKG2A-HLA-E interactions between CD8 T cells/NK cells and tumor cells.